T
Thierry Alcindor
Researcher at McGill University Health Centre
Publications - 104
Citations - 4191
Thierry Alcindor is an academic researcher from McGill University Health Centre. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 24, co-authored 83 publications receiving 2987 citations. Previous affiliations of Thierry Alcindor include McGill University & Mayo Clinic.
Papers
More filters
Journal ArticleDOI
Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial
Ian Judson,Jaap Verweij,Hans Gelderblom,Jörg T. Hartmann,Jörg T. Hartmann,Patrick Schöffski,Jean-Yves Blay,J. Martijn Kerst,Josef Sufliarsky,Jeremy Whelan,Peter Hohenberger,Anders Krarup-Hansen,Thierry Alcindor,Thierry Alcindor,Sandrine Marreaud,Saskia Litière,Catherine Hermans,Cyril Fisher,Pancras C.W. Hogendoorn,A Paolo dei Tos,Winette T. A. van der Graaf +20 more
TL;DR: This phase 3 randomised controlled trial assessed whether dose intensification of doxorubicin with ifosfamide improves survival of patients with advanced soft-tissue sarcoma compared with doxorbicin alone.
Journal ArticleDOI
2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer.
Dominique Farge,Dominique Farge,Corinne Frere,Jean M. Connors,Cihan Ay,Alok A. Khorana,Andrés Muñoz,Benjamin Brenner,Ajay K. Kakkar,Hanadi Rafii,Susan Solymoss,Dialina Brilhante,Manuel Monreal,Henri Bounameaux,Ingrid Pabinger,James D. Douketis,Walter Ageno,Fernando Ajauro,Kamal R. Al-Aboudi,Thierry Alcindor,Thierry André,Pantep Angchaisuksiri,Darko Antic,Juan I. Arcelus,Eric Assenat,Kenneth A. Bauer,Ali Bazarbachii,I. Benzidia,Jan Beyer-Westendorf,Viktoria Bitsadze,Dorit Blickstein,Mark Blostein,Isabel Bogalho,Barbara Bournet,Patricia Casais,Antoine F. Carpentier,Gabriela Cesarman-Maus,Joydeep Chakbrabartty,Hugo A. Clemente,Jérôme Connault,Ludovic Doucet,Cécile Durant,Joseph Emmerich,Anna Falanga,Clemens Feistritzer,Carme Font,Charles W. Francis,Enrique Gallardo,Thomas Gary,Jean-Christophe Gris,Cecilia Guillermo,A. Hij,Russel D. Hull,Takayuki Ikezoe,Luis Jara-Palomares,Nigel S. Key,Jamilya Khrizroeva,Maral Koolian,Florian Langer,Ramón Lecumberri,Lai Heng Lee,Howard A. Liebman,Luisa Lopes Dos Santos,Duarte Henrique Machado,Isabelle Madelaine,Alexander Makatsariya,Mario Mandalà,Anthony Marayevas,Zora Marjanovic,Christine Marosi,Ellis Martin,Luis Meillon,Emmanuel Messas,Antonio Moreira,Ahmet M. Demir,Arlette Ndour,Michel Nguessan,Remedios Otero-Candelera,Vanessa Pachon Olmos,Ana Pais,Florian Posch,Matthias Preusser,Hanno Riess,Marc Philip Righini,Cynthia Rothschild,Andre Roussin,José Antonio Rueda-Camino,Pedro Ruiz-Artacho,Sanjith Saseedharan,Ali Shamseddine,Gerald A. Soff,Hans Stricker,Vicky Tagalakis,Ali T. Taher,Toutou Toussaint,Javier Trujillo-Santos,Stéphane Villiers,Raymond S.M. Wong,Norizaku Yamada +98 more
TL;DR: The 2019 International Initiative on Thrombosis and Cancer clinical practice guidelines, which are based on a systematic review of the literature published up to December, 2018, are presented along with a Grading of Recommendations Assessment Development and Evaluation scale methods.
Journal ArticleDOI
Oxaliplatin: a review in the era of molecularly targeted therapy
Thierry Alcindor,N. Beauger +1 more
TL;DR: Oxaliplatin lends itself to further clinical research in combination with molecularly targeted therapy, and has a complicated pharmacokinetic profile, with activity against digestive cancers in particular.
Journal ArticleDOI
Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial.
William D. Tap,Hans Gelderblom,Emanuela Palmerini,Jayesh Desai,Sebastian Bauer,Jean-Yves Blay,Thierry Alcindor,Kristen N. Ganjoo,Javier Martin-Broto,Christopher W. Ryan,David Thomas,Charles Peterfy,John H. Healey,Michiel A. J. van de Sande,Heather L. Gelhorn,Dale Shuster,Qiang Wang,Antoine Yver,Henry H. Hsu,Paul S. Lin,Sandra Tong-Starksen,Silvia Stacchiotti,Andrew J. Wagner +22 more
TL;DR: Pexidartinib is the first systemic therapy to show a robust tumour response in TGCT with improved patient symptoms and functional outcomes; mixed or cholestatic hepatotoxicity is an identified risk.
Journal ArticleDOI
Results of an International Randomized Phase III Trial of the Mammalian Target of Rapamycin Inhibitor Ridaforolimus Versus Placebo to Control Metastatic Sarcomas in Patients After Benefit From Prior Chemotherapy
George D. Demetri,Sant P. Chawla,Isabelle Ray-Coquard,Axel Le Cesne,Arthur P. Staddon,Mohammed M. Milhem,Nicolas Penel,Richard F. Riedel,B. Bui-Nguyen,Lee D. Cranmer,Peter Reichardt,Emmanuelle Bompas,Thierry Alcindor,Daniel A. Rushing,Yang Song,Ruey Min Lee,Scot Ebbinghaus,Joseph E. Eid,John W. Loewy,Frank G. Haluska,Pierre F. Dodion,Jean-Yves Blay +21 more
TL;DR: Ridaforolimus delayed tumor progression to a small statistically significant degree in patients with metastatic sarcoma who experienced benefit with prior chemotherapy and provided a foundation on which to further improve control of sarcomas.